Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is well-positioned for sustained long-term revenue growth as the market for next-generation diagnostic tests continues to expand. With strong sales of its Afirma and Decipher tests, as well as upcoming launches of the Percepta Nasal Swab test and kitted versions of its tests in Europe, the company has a solid foundation for mid-teens or better revenue growth. Additionally, the recent acquisition of C2i Genomics and its TrueMRD test for bladder cancer further expands Veracyte's potential in the rapidly growing market for genomic diagnostics. While there are risks such as weaker sales and margins, the company's strong financials and pipeline indicate a positive outlook for Veracyte's stock.

Bears say

Veracyte is a leading genomic diagnostics company with potential upside from its Decipher and Afirma tests, strong revenue growth potential, and potential for better operating margins and free cash flow. However, it also faces potential downside risks due to weaker sales growth and operating margins, leading to a possible bear case scenario and price target of $24 based on an EV/sales multiple of 2.5x our 2027E sales estimate.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.